Novel antidiabetic drugs and cardiovascular risk: Primum non nocere

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 26, Issue 9, 2016, Pages 759-766

  Bonadonna, R C ^a   Borghi, C ^b   Consoli, A ^c   Volpe, M ^d,e  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e IRCCS NEUROMED   (Italy)

Author keywords

Antihyperglycemic drugs; Cardiovascular risk; Diabetes

Indexed keywords

ALBIGLUTIDE; ALOGLIPTIN; ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; DULAGLUTIDE; EMPAGLIFLOZIN; EXENDIN 4; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; BENZHYDRYL DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSIDE; INCRETIN;

ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; MORTALITY; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

BENZHYDRYL COMPOUNDS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; PATIENT SAFETY; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; SITAGLIPTIN PHOSPHATE; TREATMENT OUTCOME;

EID: 84978427983     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2016.05.007     Document Type: Article

References (44)

1. [1] Study, G.B.D., Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386 (2015), 743–800.
2. [2] Seshasai, S.R., Kaptoge, S., Thompson, A., Di Angelantonio, E., Gao, P., Sarwar, N., et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364 (2011), 829–841.
3. [3] Nichols, G.A., Gullion, C.M., Koro, C.E., Ephross, S.A., Brown, J.B., The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27 (2004), 1879–1884.
4. [4] Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R., Neil, H.A., 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008), 1577–1589.
5. [5] McMurray, J.J., Gerstein, H.C., Holman, R.R., Pfeffer, M.A., Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2 (2014), 843–851.
6. [6] Kahn, S.E., Haffner, S.M., Heise, M.A., Herman, W.H., Holman, R.R., Jones, N.P., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 (2006), 2427–2443.
7. [7] Nissen, S.E., Wolski, K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007), 2457–2471.
8. [8] Mahaffey, K.W., Hafley, G., Dickerson, S., Burns, S., Tourt-Uhlig, S., White, J., et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J, 166, 2013 240–249 e1.
9. [9] Home, P.D., Pocock, S.J., Beck-Nielsen, H., Curtis, P.S., Gomis, R., Hanefeld, M., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373 (2009), 2125–2135.
10. [10] Komajda, M., McMurray, J.J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Pocock, S.J., et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 31 (2010), 824–831.
11. [11] EMA, Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) CPMP/EWP/1080/00 Rev 1. 2012 http://wwwemaeuropaeu/ [assessed 07.12.15].
12. [12] FDA/CDER, Guidance for industry. Diabetes mellitus — Evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) http://wwwfdagov/cder/guidance/indexhtm [assessed 07.12.15].
13. [13] Hirshberg, B., Raz, I., Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs. Diabetes Care 34:Suppl. 2 (2011), S101–S106.
14. [14] Smith, C.M., Origin and uses of primum non nocere–above all, do no harm!. J Clin Pharmacol 45 (2005), 371–377.
15. [15] Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58 (2015), 429–442.
16. [16] Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes care 38 (2015), 140–149.
17. [17] Drucker, D.J., Nauck, M.A., The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006), 1696–1705.
18. [18] Meier, J.J., GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8 (2012), 728–742.
19. [19] Scheen, A.J., A review of gliptins for 2014. Expert Opin Pharmacother 16 (2015), 43–62.
20. [20] Bonora, E., Cigolini, M., DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives. Nutr Metab Cardiovasc Dis 26 (2016), 273–284.
21. [21] DeFronzo, R.A., Davidson, J.A., Del Prato, S., The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 14 (2012), 5–14.
22. [22] Kamran, M., Peterson, R.G., Dominguez, J.H., Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats. J Am Soc Nephrol 8 (1997), 943–948.
23. [23] Rahmoune, H., Thompson, P.W., Ward, J.M., Smith, C.D., Hong, G., Brown, J., Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54 (2005), 3427–3434.
24. [24] Fioretto, P., Giaccari, A., Sesti, G., Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovasc Diabetol, 14, 2015, 142.
25. [25] Pfeffer, M.A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H.C., Kober, L.V., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
26. [26] Scirica, B.M., Bhatt, D.L., Braunwald, E., Steg, P.G., Davidson, J., Hirshberg, B., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
27. [27] White, W.B., Cannon, C.P., Heller, S.R., Nissen, S.E., Bergenstal, R.M., Bakris, G.L., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369 (2013), 1327–1335.
28. [28] Zannad, F., Cannon, C.P., Cushman, W.C., Bakris, G.L., Menon, V., Perez, A.T., et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385 (2015), 2067–2076.
29. [29] Engel, S.S., Golm, G.T., Shapiro, D., Davies, M.J., Kaufman, K.D., Goldstein, B.J., Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol, 12, 2013, 3.
30. [30] Williams-Herman, D., Engel, S.S., Round, E., Johnson, J., Golm, G.T., Guo, H., et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord, 10, 2010, 7.
31. [31] Green, J.B., Bethel, M.A., Armstrong, P.W., Buse, J.B., Engel, S.S., Garg, J., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
32. [32] Bethel, M.A., Engel, S.S., Green, J.B., Huang, Z., Kaufman, K.D., Standl, E., et al. Assessing the safety of sitagliptin in elderly participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabet Med Basic Clin Sci Posters Type 2 Diabetes, 33(Suppl. 1), 2016, 86.
33. [33] Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
34. [34] Wu, J.H., Foote, C., Blomster, J., Toyama, T., Perkovic, V., Sundstrom, J., et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 4 (2016), 411–419.
35. [35] Bush, M.A., Matthews, J.E., De Boever, E.H., Dobbins, R.L., Hodge, R.J., Walker, S.E., et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab 11 (2009), 498–505.
36. [36] Jimenez-Solem, E., Rasmussen, M.H., Christensen, M., Knop, F.K., Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes. Curr Opin Mol Ther 12 (2010), 790–797.
37. [37] Holman, R.R., Bethel, M.A., George, J., Sourij, H., Doran, Z., Keenan, J., et al. Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. Am Heart J 174 (2016), 103–110.
38. [38] Marso, S.P., Poulter, N.R., Nissen, S.E., Nauck, M.A., Zinman, B., Daniels, G.H., et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J, 166, 2013 823–30 e5.
39. [39] Marx, N., Rosenstock, J., Kahn, S.E., Zinman, B., Kastelein, J.J., Lachin, J.M., et al. Design and baseline characteristics of the CARdiovascular outcome trial of LINAgliptin versus glimepiride in type 2 diabetes (CAROLINA(R)). Diab Vasc Dis Res 12 (2015), 164–174.
40. [40] Rosenstock, J., Marx, N., Neubacher, D., Seck, T., Patel, S., Woerle, H.J., et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol, 14, 2015, 57.
41. [41] McMurray, J.J., The vildagliptin in ventricular dysfunction diabetes (VIVIDD) trial. Abstract 99 The Heart Failure Congress; May 25-28, 2013; Lisbon, Portugal, 2013.
42. [42] Krum, H., Lukashevich, V., Bolli, G., Kozlovski, P., Kothny, W., Ponikowski, P., No significant difference in risk of heart failure hospitalization with vildagliptin in diabetic patients with systolic chronic heart failure: Vividd Study. American Diabetes Association 74th Scientific Sessions; 2014 Jun 15; San Francisco, CA, 2014.
43. [43] Neal, B., Perkovic, V., de Zeeuw, D., Mahaffey, K.W., Fulcher, G., Stein, P., et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)–a randomized placebo-controlled trial. Am Heart J, 166, 2013 217–23 e11.
44. [44] DeFronzo, R.A., The EMPA-REG study: what has it told us? A diabetologist's perspective. J Diabetes Complicat 30 (2016), 1–2.